Testing atezolizumab plus bevacizumab with SBRT for advanced liver cancer
Treatments studied
Part of Cancer clinical trials.
This Phase 1 trial tests how well a combination treatment works for liver cancer that cannot be removed with surgery or other local treatments. It combines two immune/targeted medicines with a focused type of radiation (SBRT) to control the tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hepatocellular carcinoma (HCC) and your cancer cannot be removed with surgery, transplant, or radiofrequency ablation (RFA).
- Your scans show at least one measurable liver tumor (or a tumor blood-vessel blockage) and imaging was done within the last month.
- You may have a small amount of spread outside the liver (up to a total size limit under 2 cm).
- Your liver function must be in Child-Pugh Class A, and you must not have major problems from high pressure in the portal vein system.
- Blood counts and organ function must meet lab limits, and your overall health must be good (ECOG 0–1).
- You cannot have had prior cancer treatment taken as a whole-body medicine; certain recent radiation and other cancer therapies also exclude you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination therapy for liver cancer that cannot be surgically removed. It uses an immune-boosting drug (atezolizumab), a drug that blocks blood flow to tumors (bevacizumab), and a type of chemotherapy that is delivered directly into the liver artery (HAIC). This combination may help shrink liver tumors and improve outcomes.
This Phase 2 study tests whether atezolizumab combined with a multi-targeted (“multi-kinase”) inhibitor can treat advanced liver cancer that cannot be cured with surgery or local procedures. It focuses on people whose cancer has already grown despite a first-line treatment using atezolizumab plus bevacizumab.
This study looks at how adding local treatments (like targeted radiation or chemotherapy directly to the liver tumor) to your current immunotherapy and targeted therapy combination might affect outcomes for people with advanced liver cancer. It aims to find out which patients benefit most from adding these extra treatments.
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) plus targeted proton radiation for liver cancer that cannot be removed by surgery. The goal is to see if this approach can shrink tumors and improve outcomes for people with intermediate or advanced stage liver cancer.
This trial tests whether adding a precise, targeted form of radiation (called SBRT) to standard immunotherapy (atezolizumab and bevacizumab) can help people with advanced liver cancer that has spread to the blood vessels or outside the liver. You may be asked to participate in one of two treatment groups to see which approach works better.
This trial tests adding two immunotherapy and anti-angiogenesis drugs (atezolizumab and bevacizumab) to standard photon radiation for people with liver cancer that cannot be surgically removed. It aims to see if this combination can shrink tumors and improve outcomes.
Hear when a new Unresectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.